Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.44 |
| ▸ | PDE4A | P27815 | 4/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.44 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.41 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.41 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | PLAT | P00750 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12157392 | 0.90 | MGLL (0.44) | ENPP2ROCK2ROCK1PDE4BPDE4A | |
| SCHEMBL22736369 | 0.89 | ROCK2 (0.44) | ENPP2ROCK2ROCK1PDE4BPDE4A | |
| SCHEMBL26702092 | 0.83 | HSD17B10 (0.42) | ENPP2ROCK2ROCK1ALDH1A1KDM4E | |
| SCHEMBL13385087 | 0.82 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4DNR1H4 | |
| SCHEMBL5840798 | 0.82 | EGFR (0.41) | ENPP2NR1H4HTTKDM4EL3MBTL1 | |
| SCHEMBL14176639 | 0.79 | SCN8A (0.45) | PDE4BPDE4APDE4CPDE4DNR1H4 | |
| SCHEMBL910660 | 0.78 | ALDH1A1 (0.44) | ENPP2ORAI1ORAI2ORAI3ALDH1A1 | |
| SCHEMBL21933 | 0.78 | ALDH1A1 (0.48) | ENPP2ALDH1A1PDCD1CD274BACE1 | |
| SCHEMBL29838597 | 0.78 | ALDH1A1 (0.48) | ENPP2ALDH1A1PDCD1CD274BACE1 | |
| Benzene SCHEMBL28163950 | 0.78 | ALDH1A1 (0.48) | ENPP2ALDH1A1PDCD1CD274BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112552291-B | Organic electroluminescent material and organic electroluminescent device thereof | 河北瑞芯电子新材料有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-112552291-A | Organic electroluminescent material and organic electroluminescent device thereof | 河北瑞芯电子新材料有限公司 | 2021-03-26 | — | — | CN | disclosed |
| US-9776995-B2 | Bicyclic sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160137636-A1 | Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors | AMGEN INC. | 2016-05-19 | — | — | US | disclosed |
| US-20150266892-A1 | AMPK Modulators | MERCURY THERAPEUTICS INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-8980895-B2 | AMPK modulators | MERCURY THERAPEUTICS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| WO-2014201173-A1 | BICYCLIC SULFONAMIDE COMPOUNDS AS SODIUM CHANNEL INHIBITORS | AMGEN INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| US-20120302576-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. | 2012-11-29 | — | — | US | disclosed |
| US-8273744-B2 | AMPK modulators | MERCURY THERAPEUTICS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2240016-A1 | AMPK MODULATORS | Mercury Therapeutics, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20100009992-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. | 2010-01-14 | — | — | US | disclosed |
| WO-2009100130-A1 | AMPK MODULATORS | MERCURY THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266892-A1 | AMPK Modulators | PRKAG1, PRKAG2, PRKAG3 | ENPP2 2338/4885ROCK2 1793/4885ROCK1 1696/4885 |
| US-20120302576-A1 | AMPK MODULATORS | PRKAG1, PRKAG2, PRKAG3 | ENPP2 2338/4885ROCK2 1793/4885ROCK1 1696/4885 |
| US-20100009992-A1 | AMPK MODULATORS | PRKAG1, PRKAG2, PRKAG3 | ENPP2 2338/4885ROCK2 1793/4885ROCK1 1696/4885 |
| US-20160137636-A1 | Bicyclic Sulfonamide Compounds as Sodium Channel Inhibitors | SCN7A, SCN1A, SCN5A | ENPP2 1460/4885ROCK2 4642/4885ROCK1 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.